Sector News

AstraZeneca divests gastrointestinal drug for $215 million

July 9, 2015
Life sciences
AstraZeneca struck a further “externalization” deal on Thursday to help fill its short-term revenue gap by divesting its gastrointestinal drug Entocort for $215 million.
 
The British drugmaker, which has high hopes for its new drug pipeline but faces declining sales as older products lose patent protection, said rights to Entocort outside the United States would be acquired by Tillotts Pharma, part of the Zeria Group.
 
Entocort, or budesonide, is used to treat patients with mild to moderate Crohn’s disease and ulcerative colitis. It is sold in more than 40 countries and had sales of $53 million outside the United States in 2014.
 
The transaction is expected to complete in the second half of 2015 and AstraZeneca said it would reinforce its strategic focus on selected therapy areas, such as cancer, respiratory disease and diabetes.
 
Chief Executive Pascal Soriot argues that spinning off non-core businesses like Entocort will help the company’s finances and allow it to invest for the future, but some analysts are worried about its reliance on such deals.
 
The issue came to a head in April when AstraZeneca said it was getting a $450 million windfall by letting Celgene develop a prized immunotherapy drug for blood cancers.
 
Soriot has also struck cash-generating externalization deals with Eli Lilly in Alzheimer’s and with Daiichi Sankyo for a new constipation drug.
 
(Reporting by Ben Hirschler; Editing by Pravin Char)

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.